<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662883</url>
  </required_header>
  <id_info>
    <org_study_id>KET-PK-009</org_study_id>
    <nct_id>NCT00662883</nct_id>
  </id_info>
  <brief_title>Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)</brief_title>
  <official_title>A Randomized, Open Label Study to Assess the Effects of a Nasal Corticosteroid on the Pharmacokinetics, Safety, and Tolerability of PMI-150 (Intranasal Ketamine Hydrochloride) 30 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Javelin Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Javelin Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effects of nasal corticosteroid treatment on the rate and extent of intranasal
      absorption of PMI-150 (intranasal ketamine HCl)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will participate in a two-period, single-sequence study to assess the effects of
      administration of a nasal corticosteroid, Nasonex (mometasone furoate), on the
      pharmacokinetics, safety and tolerability of PMI-150 (intranasal ketamine HCl) in healthy
      adult volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PMI-150 (intranasal ketamine HCl), day 1
mometasone furoate, days 2-15
PMI-150 (intranasal ketamine HCl), day 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PMI-150 (intranasal ketamine HCl); mometasone furoate</intervention_name>
    <description>1 dose PMI-150 (intranasal ketamine HCl); day 1
mometasone furoate, daily; days 2-15
1 dose PMI-150 (intranasal ketamine HCl); day 15</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Nasonex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy adults

          -  nonsmoker

          -  no drug use

        Exclusion Criteria:

          -  nasal abnormalities

          -  airway abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javelin Pharmaceuticals, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Javelin Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>April 21, 2008</last_update_submitted>
  <last_update_submitted_qc>April 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Javelin Pharmaceuticals, Inc.</name_title>
    <organization>Javelin Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>ketamine</keyword>
  <keyword>corticosteroid</keyword>
  <keyword>intranasal</keyword>
  <keyword>phase I</keyword>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

